Trial Profile
A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jun 2019
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Temsirolimus (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Jun 2018 Status changed from active, no longer recruiting to completed.
- 17 Apr 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
- 17 Apr 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.